摘要
目的回顾性分析晚期非小细胞肺癌(NSCLC)在二线表皮生长因子受体酪氨酸激酶抑制剂(EGFRTKI)治疗失败后接受不同治疗方案对无进展生存期及生存时间的关系。方法收集我院2007年1月1日—2012年5月1日具有明确细胞或组织学类型,临床分期为ⅢB或Ⅳ期的NSCLC患者120例,且明确接受过二线靶向治疗后经证实疾病进展的相关临床资料。结果 120例患者EGFR-TKI治疗经证实失败后,分别接受了最佳支持治疗(BSC),单药化疗以及含铂方案的两药联合化疗,对其基本情况进行分析,显示不同方案的无进展生存期(Progression-Free Survival,PFS)和整体生存期(Overall Survival,OS)与性别、年龄无关;化疗,尤其是含铂方案的联合化疗能明显提高其疾病无进展期及生存时间,P均<0.05,差异具有统计学意义。结论晚期NSCLC患者在靶向治疗失败后,化疗,尤其是含铂方案的联合化疗能明显提高患者的PFS及生存时间。
Objective To compare different therapeutic regimens in patients with advanced non-small-cell lung cancer （NSCL） after failed second-line molecular targeting therapy. Methods One hundred and twenty patients with advanced NSCLC were admitted from January 2007 to May 2012. Results After the failure of EGFR-TKI targeting therapy patients received best supporting care （BSC, n = 28 ） , monochemotherapy （ n = 38 ） or platinum-doublet chemotherapy （ n = 54 ）. Progression-free survival （PFS）and overall survival （OS）were retrospectively analyzed in three groups. Both the OS and PFS in patients treated with platinum-based combined chemotherapy were longer than those treated with BSC and monochemotherapy （ P 〈 0. 05 ）. Conclusion Platinum-based combined chemotherapy may improve the survival of advanced NSCL patients after failed molecular targeting therapy.
出处
《同济大学学报（医学版）》
CAS
2013年第6期67-70,共4页
Journal of Tongji University(Medical Science)
